X4 Pharmaceuticals announces common stock offering, no amount given

X4 Pharmaceuticals (XFOR) announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities are being offered by X4. X4 intends to use the net proceeds from this offering to fund the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders, as well as for general and administrative expenses, capital expenditures, working capital and other general corporate purposes. Leerink Partners, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering.